Aaltomaa S, Lipponen P, Vesalainen S, Ala-Opas M, Eskelinen M, Syrjänen K
Department of Urology, University of Kuopio, Finland.
Eur Urol. 1997;32(4):410-5.
OBJECTIVE(S): The aim of the study was to analyze the results of Ki-67 immunostaining in prostatic adenocarcinoma and to assess its prognostic value.
Clinical follow-up data was reviewed in 190 prostatic adenocarcinomas and the results of Ki-67 immunolabelling were correlated to standard prognostic factors and survival data of the patients. All stage and grade categories were included.
Ki-67 expression correlated significantly with histological differentiation of tumors, indicators of cell proliferation, perineural growth, density of tumor-infiltrating lymphocytes and TM classification. In survival analysis, Ki-67 expression was able to discriminate patients into different prognostic groups (p = 0.0035). In a separate analysis including T1-2M0 tumors, Ki-67 immunolabelling was a significant predictor of survival (p = 0.0258). In Cox's multivariate analysis Ki-67 was an independent prognostic factor in the entire cohort.
The results show that Ki-67 expression is a potentially useful prognostic factor in prostatic adenocarcinoma and it could be used as an additional criterion in defining a correct prognostic category in this malignancy.
本研究旨在分析前列腺腺癌中Ki-67免疫染色的结果，并评估其预后价值。
回顾了190例前列腺腺癌的临床随访数据，并将Ki-67免疫标记结果与患者的标准预后因素和生存数据相关联。纳入了所有分期和分级类别。
Ki-67表达与肿瘤的组织学分化、细胞增殖指标、神经周围生长、肿瘤浸润淋巴细胞密度和TM分类显著相关。在生存分析中，Ki-67表达能够将患者分为不同的预后组（p = 0.0035）。在一项包括T1-2M0肿瘤的单独分析中，Ki-67免疫标记是生存的显著预测因子（p = 0.0258）。在Cox多变量分析中，Ki-67是整个队列中的独立预后因素。
结果表明，Ki-67表达是前列腺腺癌中一个潜在有用的预后因素，可作为该恶性肿瘤正确预后分类的附加标准。
